Navigation Links
Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
Date:3/4/2013

LA JOLLA, Calif., March 4, 2013Sanford-Burnham Medical Research Institute (Sanford-Burnham) and 60 Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics. 60 Pharmaceuticals, a philanthropic-for-profit company focused on neglected and rare diseases, agreed to provide funding to Sanford-Burnham for the first phase of research to explore inhibitors of furin.

Since viral genomes are too small to encode every protein needed for their survival, they take advantage of proteins in their human hosts. For the dengue virus and numerous other virusessuch as West Nile, Ebola, or yellow feverfurin is a vital host protein. For this reason, these viruses can only attack human cells that produce furin. Scientists at Sanford-Burnham are now trying to find a way to inhibit furin, making it impossible for the dengue virus to exploit and "hijack" a host cell.

"We're working on a new small-molecule furin inhibitor. It's a challenge to design, but could solve the toxicity problem that plagues existing viral inhibitors," explains Alex Strongin, Ph.D., professor in Sanford-Burnham's Infectious and Inflammatory Disease Center.

During the first phase of the research partnership, Drs. Alex Strongin and Maurizio Pellecchia and their laboratories at Sanford-Burnham will identify the most promising lead candidate from multiple small-molecule compounds they have already synthesized and tested in cell-based tests. They will evaluate each compound's absorption and distribution in the body (pharmacokinetics), as well as toxicity and efficacy in animal models. These data will inform potential second-phase research, which will focus on further developing the lead compound for oral application.

"The partnership with Sanford-Burnham exemplifies our commitment to developing treatments for the world's most challenging and neglected diseases, such as dengue fever," adds Geoffrey Dow, CEO of 60 Pharmaceuticals. "Only a combined effort can help address these challenges and make a real difference in the lives of millions of people living in regions affected by the dengue virus. Our goal is to find a treatment that is affordable, safe in warm and humid climates, and easy to administer."

Successfully designing a small-molecule inhibitor of furin that is safe and effective could have implications far beyond dengue fever. Given the protein's prevalence and important role in the lifecycle of a variety of viruses, a potent inhibitor could eventually lead to treatment options for many more viral diseases, affecting hundreds of millions of people worldwide.


'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-745-2073
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Californias stem cell agency boosts heart disease research at Sanford-Burnham
2. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
3. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
6. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
9. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
10. Researchers pursue red flag for schizophrenia relapse
11. University of Arizona Engineering College pursues water technology innovation cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2019)... , ... May 24, 2019 , ... The newest edition ... is now available on the company’s global website. , Crystallography Times is a monthly ... X-ray diffraction. It serves the X-ray analysis community by presenting the latest news and ...
(Date:5/23/2019)... , ... May 23, 2019 , ... ... Agents for sales and service organizations, today announced its inclusion in DMG ... Solutions as the intelligent virtual agent (IVA) market share leader, based on number ...
(Date:5/21/2019)... ... May 21, 2019 , ... Experiential tourism, a trend encompassing culinary travel, ... last several years. And according to a recent report by Skift, a media ... fact, more and more travelers are wanting their journeys to be authentic and unique, ...
Breaking Biology News(10 mins):
(Date:5/15/2019)... ... May 15, 2019 , ... Milton Hershey School® has named William Charles ... within the biomedical industry, where he is changing lives by creating solutions to global ... Harding epitomizes the vision of our founders – Milton and Catherine Hershey – who ...
(Date:5/14/2019)... , ... May 14, 2019 , ... Gateway Genomics ... effectively doubling its space from 2,500 to 5,000 square feet. , “This past ... DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, which ...
(Date:5/4/2019)... ... May 03, 2019 , ... More than three ... Pesquisas Association, the scientist and ufologist Urandir Fernandes de Oliveira, last Thursday (25), ... the results of some research carried out by the association, in partnership with ...
(Date:5/2/2019)... ... 2019 , ... The centuries old practice of brewing beer thrives today across ... and even home brewing clubs scattered across the nation. , But proper beer ... can produce a superb product. Students at South Dakota School of Mines & ...
Breaking Biology Technology: